Sieberns S
Fortschr Med. 1979 Oct 11;97(38):1705-8.
The efficacy and the compatibility of the new anxiolytic Trecalmo (Clotiazepam) were investigated by means of a field trial covering 186 patients, suffering from anxiety and tension as well as from psychosomatic disorders. The new drug proved to be remarkably effective in symptoms as anxiety, restlessness, irritations, tension headache as well as functional cardiovascular diseases and digestive disorders. The compatibility was good.
通过一项涵盖186名患有焦虑、紧张以及身心疾病患者的现场试验,对新型抗焦虑药曲卡莫(氯噻西泮)的疗效和耐受性进行了研究。结果表明,这种新药对焦虑、烦躁、易怒、紧张性头痛以及功能性心血管疾病和消化系统疾病等症状具有显著疗效,耐受性良好。